Mathieu Gigoux, Morten O Holmström, Roberta Zappasodi, Joseph J Park, Stephane Pourpe, Cansu Cimen Bozkus, Levi M B Mangarin, David Redmond, Svena Verma, Sara Schad, Mariam M George, Divya Venkatesh, Arnab Ghosh, David Hoyos, Zaki Molvi, Baransel Kamaz, Anna E Marneth, William Duke, Matthew J Leventhal, Max Jan, Vincent T Ho, Gabriela S Hobbs, Trine Alma Knudsen, Vibe Skov, Lasse Kjær, Thomas Stauffer Larsen, Dennis Lund Hansen, R Coleman Lindsley, Hans Hasselbalch, Jacob H Grauslund, Thomas L Lisle, Özcan Met, Patrick Wilkinson, Benjamin Greenbaum, Manuel A Sepulveda, Timothy Chan, Raajit Rampal, Mads H Andersen, Omar Abdel-Wahab, Nina Bhardwaj, Jedd D Wolchok, Ann Mullally, Taha Merghoub
The majority of JAK2V617F -negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin ( CALR ), resulting in a common carboxyl-terminal mutant fragment (CALRMUT ), representing an attractive source of neoantigens for cancer vaccines. However, studies have shown that CALRMUT -specific T cells are rare in patients with CALRMUT MPN for unknown reasons. We examined class I major histocompatibility complex (MHC-I) allele frequencies in patients with CALRMUT MPN from two independent cohorts...
June 15, 2022: Science Translational Medicine